Loss of contrast intensity during systole in the left ventricular cavity with the use of the contrast agent Albunex. An analysis of its correlation with pressure and velocity

Improvement of Detection Sensitivity of Microbubbles as Sensors to Detect Ambient Pressure

Microbubbles are considered a promising tool for noninvasive estimation of local blood pressure. It is reported that the subharmonic scattering amplitude of microbubbles decreases by 9 to 12 dB when immersed in the media under an ambient pressure variation from 0 to 180 mmHg. However, the pressure sensitivity still needs to be improved to satisfy clinical diagnostic requirements. Here, we investigated the effects of acoustic parameters on the pressure sensitivity of microbubbles through measuring the acoustic attenuation and scattering properties of commercially available SonoVue microbubbles. Our results showed that the first harmonic, subharmonic, and ultraharmonic amplitudes of microbubbles were reduced by 6.6 dB, 10.9 dB, and 9.3 dB at 0.225 mechanical index (MI), 4.6 dB, 19.8 dB, and 12.3 dB at 0.25 MI, and 18.5 dB, 17.6 dB, and 12.6 dB at 0.3 MI, respectively, when the ambient pressure increased from 0 to 180 mmHg. Our finding revealed that a moderate MI (0.25–0.4) exciting microbubbles could significantly improve their sensitivities to detect ambient pressure.

Simulation of noninvasive blood pressure estimation using ultrasound contrast agent microbubbles

The microbubble ultrasound contrast agent (UCA) has been widely recognized as a potential noninvasive tool for blood pressure measurement. However, UCA indices such as the shift in the resonance frequency and echo amplitude have problems of low resolution, nonlinear relationship with blood pressure, etc. In this paper, a novel UCA index, the shift in the subharmonic optimal driving frequency (SSODF) of microbubbles, is proposed. The effectiveness of the index for estimating blood pressure was evaluated by performing a microbubble acoustic response simulation. The behavior of commercial UCA microbubbles was investigated as a function of the driving acoustic pressure (in kilopascals) and ambient overpressure (in millimeters of mercury). Simulation results showed that for a 1.6-μm-diameter microbubble, SSODF increased linearly with the overpressure in a range of 0 to 200 mmHg and was maximum (2.07 MHz) at 380 kPa. Changes of the overpressure as small as 5 mmHg can be detected using SSODF. For a population of microbubbles with a Gaussian size distribution (mean diameter: 1.6 μm, standard deviation: 0.2 μm), SSODF was 1.7 MHz at 280 kPa. With further experimental validation, the proposed method may be developed as a novel noninvasive technique for accurate blood pressure measurement.

Intracavitary contrast intensity after transpulmonary transmission of a second-generation contrast agent at normal and reduced myocardial contractility

In this closed-chest preparation in 10 anesthetized pigs, we determined the effects of left ventricular (LV) contractility changes on the echocardiographic contrast intensity variation of a second-generation contrast agent within the LV cavity. The peak positive rate of change in LV pressure (dP/dt(max)), as an index of the isovolumetric phase, was gradually reduced by administration of halothane and propranolol, and the velocity of circumferential fiber shortening (Vcfs) was referenced as an index for the LV ejection phase. Contrast intensity-time curves of the LV cavity were obtained after transpulmonary transmission of the contrast agent. An off-line densitometric method was performed to determine peak maximum and minimum intensities (I(max), I(min)) and their difference (I(amp)). Compared with baseline values, at reductions in dP/dt(max) of 50% and 75%, the contrast intensity parameters I(max), I(min), and I(amp) were decreased by 23% +/- 6% and 44% +/- 5%, 24% +/- 5% and 44% +/- 3%, and 31% +/- 6% and 45% +/- 3%, respectively (P <.05). Significant correlations were observed between I(amp) and dp/dt(max) (r = 0.82, P <.003, n = 30) and their changes (r = 0.59, P <.03, n = 20), but correlations between contrast indexes and Vcfs were only moderate. The sensitivity of I(amp) to indicate changes in dP/dt(max) and Vcfs was 0.95 and 0.83, respectively. The cyclic variation of LV intracavitary contrast intensity reflects the isovolumetric contraction phase better than the ejection phase. The results suggest that measurements of cyclic intensity changes may contribute to the assessment of myocardial contractility changes. Underlying biophysical mechanisms and load dependency of this phenomenon require further investigation.

New imaging technology: measurement of myocardial perfusion by contrast echocardiography

Myocardial perfusion imaging has long been a goal for the non-invasive echocardiographic assessment of the heart. However, many factors at play in perfusion imaging have made this goal elusive. Harmonic imaging and triggered imaging with newer contrast agents have made myocardial perfusion imaging potentially practical in the very near future. The application of indicator dilution theory to the coronary circulation and bubble contrast agents is fraught with complexities and sources of error. Therefore, quantification of myocardial perfusion by non-invasive echocardiographic imaging requires further investigation in order to make this technique clinically viable.

Differing susceptibility of echocardiographic contrast agents to adverse effects of biologic factors: multicenter, videodensitometric comparison of octafluoropropane-filled microspheres with air-filled microspheres for left ventricular opacification

BACKGROUND

Echocardiographic contrast enhancement of the left ventricle has diagnostic value in the assessment of regional and global left ventricular (LV) function. The efficacy of both octafluoropropane-filled human albumin microbubbles (OCTA) and of air-filled human albumin microbubbles (AIR) for LV endocardial delineation and qualitative LV opacification has previously been reported. However, pulmonary disease, obesity, impaired LV function, and decreased echogenicity may diminish the efficacy of contrast agents for LV opacification. The purpose of this study was to compare the susceptibility of 2 contrast agents currently approved by the Food and Drug Administration to these biologic factors.

METHODS

To compare quantitative LV opacification with OCTA (0.2, 0. 5, 3.0, 5.0 mL) versus AIR (0.08 mL/kg, 0.22 mL/kg), we performed videodensitometry in 199 patients (average age 59.2 +/- 13.3 years, 79% men) studied in 2 identical, prospective, multicenter, blinded trials, of whom 74 had impaired LV function, pulmonary disease, or both, 70 were obese (body mass index >30 kg/m(2)), and 45 were nonechogenic (>/=4 of 6 endocardial segments were not seen in the apical 4-chamber view). Changes in videodensity from noncontrast to contrast agent with the same gain settings were determined at end diastole and end systole (gray scale 0 to 255 U) for 2 regions of interest: left ventricle apex-to-mid-cavity and mid-cavity-to-base. The relative influence of clinically evident pulmonary disease, impaired LV function on echocardiography, and echogenicity on LV opacification produced by both contrast agents was determined by multivariate analysis.

RESULTS

Significant videodensity increases ranging from 67% to 143% were observed with both agents. At the recommended initial doses (0.5 mL for OCTA, 0.22 mL/kg for AIR), OCTA produced greater opacification than AIR in both regions of interest and at both phases of the cardiac cycle. Poor LV function was associated with decreased LV opacification for AIR but not for OCTA. Diminished echogenicity was more strongly associated with impaired opacification for AIR than for OCTA. Obesity and clinically evident pulmonary disease were associated with diminished chamber opacification with both OCTA and AIR.

CONCLUSIONS

In addition to the superiority of octafluoropropane-filled microspheres to air-filled microspheres for LV opacification, the efficacy of OCTA is relatively unaffected by impaired LV function and is less susceptible to the effects of poor echogenicity than AIR.

Contrast enhanced pulsed Doppler and colour-coded duplex studies of the cranial vasculature

INTRODUCTION

The aim of this study was to assess the effect of Albunex, a vascular contrast agent based on albumin-coated air microbubbles, on pulsed Doppler and colour-coded duplex sonography of the cranial vasculature.

METHODS

Twenty healthy male volunteers received intravenous injections of contrast in single doses ranging from 0.08 to 0.30 ml/kg. Pulsed wave Doppler sonography examination and colour-coded duplex sonography were carried out in the right internal carotid artery (ICA) and middle cerebral artery (MCA) before and after i.v. contrast. The relative intensity increase of the Doppler signal was measured in decibels.

RESULTS

Transpulmonary passage of contrast occurred in sufficient amounts to enhance the intensity of the Doppler signal significantly, but the duration of this effect was short. Contrast enhancement also improved visualization of both the ICA and MCA in all subjects. For the transcranial examinations, this resulted in visualization of a greater length of the middle cerebral arteries and additional vessels in the Circle of Willis.

CONCLUSIONS

These results confirm that contrast enhancement can significantly improve the quality of Doppler examination and colour-coded duplex sonography of both the intracranial and extracranial vessels. However, the use of Albunex in neurosonology will be of limited value due to its relatively short duration.

Comparison of tissue harmonic imaging with contrast (sonicated albumin echocardiography and Doppler myocardial imaging for enhancing endocardial border resolution

Endocardial resolution during 2-dimensional echocardiography is technically limited in at least 10% to 15% of patients. Recently, several ultrasound imaging innovations have been introduced that may improve endocardial resolution and decrease the proportion of technically difficult studies. This study compares tissue harmonic imaging, intravenous sonicated albumin, and Doppler myocardial imaging in patients with technically difficult echocardiograms. Twenty-eight patients with known or suspected cardiac disease and poor baseline endocardial resolution were studied. Only harmonic imaging (conventional and optimized for tissue) was superior to baseline fundamental imaging (p <0.001). Harmonic imaging was superior to baseline imaging in all myocardial regions and in the majority of patients, including those with the worst baseline studies.

Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial

OBJECTIVES

The echocardiographic contrast-enhancing effects and safety profile of ALBUNEX (a suspension of air-filled albumin microspheres) were compared with the new contrast agent OPTISON (formerly FS069: a suspension of albumin microspheres containing the gas perfluoropropane) in 203 patients with inadequate noncontrast echocardiograms.

BACKGROUND

The efficacy of ALBUNEX has been limited by its short duration of action. By using perfluoropropane instead of air within the microsphere, its duration of action is increased.

METHODS

Each patient received ALBUNEX (0.8 and 0.22 mL/kg) and OPTISON (0.2, 0.5, 3.0, and 5.0 mL) on separate days a minimum of 48 hours apart. Echocardiograms were evaluated for increase in left ventricular (LV) endocardial border length, degree of LV opacification, number of LV endocardial border segments visualized, conversion from a nondiagnostic to a diagnostic echocardiogram, and duration of contrast enhancement. A thorough safety evaluation was conducted.

RESULTS

Compared with ALBUNEX, OPTISON more significantly improved every measure of contrast enhancement. OPTISON increased well-visualized LV endocardial border length by 6.0+/-5.1, 6.9+/-5.4, 7.5+/-4.7, and 7.6+/-4.8 cm, respectively, for each of the four doses, compared with only 2.2+/-4.5 and 3.4+/-4.6 cm, respectively, for the two ALBUNEX doses (p < 0.001). 100% LV opacification was achieved in 61%, 73%, 87%, and 87% of the patients with the four doses of OPTISON, but in only 16% and 36% of the patients with the two ALBUNEX doses (p < 0.001). Conversion of nondiagnostic to diagnostic echocardiograms with contrast occurred in 74% of patients with the optimal dose of OPTISON (3.0 mL) compared with only 26% with the optimal dose of ALBUNEX (0.22 mL/kg) (p < 0.001). The duration of contrast effect was also significantly greater with OPTISON than with ALBUNEX. In a subset of patients with potentially poor transpulmonary transit of contrast (patients with chronic lung disease or dilated cardiomyopathy), OPTISON more significantly improved the same measures of contrast enhancement compared with ALBUNEX and did so to the same extent as in the overall population. Side effects were similar and transient with the two agents.

CONCLUSION

OPTISON appears to be a safe, well-tolerated echocardiographic contrast agent that is superior to ALBUNEX.

Diagnosis of renal artery stenosis and renovascular hypertension

Renovascular hypertension resulting from renal artery stenosis is a potentially curable form of secondary hypertension. Although uncommon in the general hypertensive population, the prevalence of renovascular hypertension rises in selected groups of hypertensive patients. Because of the possibility of cure, screening measures for renal artery stenosis are warranted in hypertensive patients with clinical features suggestive of renovascular disease. For a long time, angiography has been considered the 'gold standard' in screening for arterial stenosis. However, it is invasive and associated with inherent morbidity. Thus, less invasive screening measures with high diagnostic sensitivity and specificity are currently being sought. Magnetic resonance angiography and captopril renal scintigraphy are safer alternatives to angiography, but are expensive and not widely available. Duplex ultrasound is more widely available and provides both anatomic and functional assessment of renal artery stenosis; however, sensitivity and specificity vary considerably among different laboratories. Echo-enhanced duplex ultrasound using the galactose-based agent Levovist(R) produces higher quality images of the renal artery than conventional color Doppler, while significantly reducing mean examination time and improving diagnostic confidence. In addition, Levovist does not compromise the safety of duplex ultrasound. Other advances in Doppler imaging techniques that may improve ultrasound sensitivity and specificity in detection of renal artery stenosis are power Doppler, echo-enhanced harmonic spectral Doppler imaging, and echo-enhanced harmonic power Doppler imaging.